Proactive Investors - Run By Investors For Investors

Scancell Holdings extends collaboration with Sweden's Karolinska Institute

The company first teamed up with Sweden's world-leading medical research university two years ago
front of the karolina institute
The two are collaborating on a technology that hunts down cancer cells previously hidden from the immune system

Scancell Holdings Plc (LON:SCLP) shares rose on Thursday on news the firm has extended its collaboration with the rheumatology unit of the Karolinska Institute, Sweden’s world-leading medical research university.

The pair will focus on broadening the applications for Scancell’s Moditope platform, building on a relationship that’s been in place for more than two years.

READ: Scancell Holdings inks drug delivery technology deal

The Moditope technology is central to one of the company’s main drug candidates, MODI-1, which initially will be trialled in breast and ovarian cancer as well as sarcoma (tumours found in fat, muscle, bone and tendons).

The Scancell innovation acts to stimulate the production of killer CD4+ T cells that seek out and kill tumour cells that would otherwise be hidden from the immune system.  

Scientists at the Karolinska Institute, led by Professors Lars Klareskog and Vivianne Malmström, uncovered an essential role for citrullinated proteins, which are normally associated with arthritis, in this process.

"We are pleased to have broadened our research collaboration with Professor Klareskog, Professor Malmström and their colleagues at the Karolinska Institute,” said Scancell’s chief scientific officer, Professor Lindy Durrant.

“Our research has shown that citrullinated proteins are involved in the control of tumour growth and we believe that this expanded collaboration will help us to   develop Moditope, not only for use in cancer vaccines but also as part of other cancer immunotherapy approaches."

In mid-morning trading, Scancell shares were 0.8% higher at 12.25p.

 -- Adds share price --

View full SCLP profile View Profile

Scancell Holdings PLC Timeline

Related Articles

knee physio
February 18 2019
Results from an eight-year clinical extension study showed that ChondroMimetic was able to regenerate cartilage to a structural quality almost identical to native cartilage
researcher filling a tray of samples
December 14 2018
The company has two clinical trials underway and is well funded to achieve its immediate ambitions
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use